In a randomised study of DLBCL in China (N = 63), first‐line R‐CHOP provided a significantly lower rate of disease progression versus CHOP (3.2% vs. 21.9%; p = 0.026), with slightly higher overall (objective response rate [ORR]; 83.8 vs. 65.6%) and complete response (CR) rates (41.9% vs. 37.5%) [10]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.